fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 5 Sep 2026

MAXHEALTH, full dossier

Max Healthcare Institute allotted 33,765 equity shares under ESOS on 04 September 2026, increasing its paid up equity share capital to 97,33,10,251 equity shares of Rs 10 each.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Max Healthcare Institute allotted 33,765 equity shares under ESOS on 04 September 2026, increasing its paid up equity share capital to 97,33,10,251 equity shares of Rs 10 each.

capitalmarket.com4 Sep 2026

Max Healthcare Institute has allotted 33,765 equity shares under ESOS on 04 September 2026.

capitalmarket.com4 Sep 2026

Max Healthcare Institute

₹940.95

▲ +1.20%

Close (EOD), as of 1 Oct 2026 · source

Max Healthcare Institute: results, dividends, orders, the full cited record →

More on Max Healthcare Institute

Hospital stocks came under pressure on Wednesday after the Supreme Court sought the Centre's response on whether a uniform cap should be imposed on the retail prices of medicines and medical devices.

30 Sep 2026 · 1 publisher

Hospital stocks Max Healthcare Institute, Apollo Hospitals Enterprise, Yatharth Hospital, Fortis Healthcare, Artemis Medicare Services, and Aster DM Quality Care crashed 5-7% in morning trade on Wednesday.

30 Sep 2026 · 1 publisher

The stock that we have today is Max Healthcare Institute.

15 Sep 2026 · 1 publisher

The stock of Max Healthcare Institute has been on a decline since early July, but after finding support at ₹980 by mid-August, the downtrend was arrested.

15 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.